Co-nanoencapsulated meloxicam and curcumin improves cognitive impairment induced by amyloid-beta through modulation of cyclooxygenase-2 in mice
Co-nanoencapsulated meloxicam and curcumin improves cognitive impairment induced by amyloid-beta through modulation of cyclooxygenase-2 in mice作者机构:Postgraduation Program in BiochemistryFederal University of Pampa(UNIPAMPA)UruguaianaRSBrazil Postgraduation Program in Pharmaceutical ScienceFederal University of Pampa(UNIPAMPA)UruguaianaRSBrazil Postgraduation Program in Biochemistry and BioprospectingFederal University of Pelotas(UFPEL)Capão do LeãoRSBrazil
出 版 物:《Neural Regeneration Research》 (中国神经再生研究(英文版))
年 卷 期:2021年第16卷第4期
页 面:780-786页
核心收录:
学科分类:0710[理学-生物学] 1002[医学-临床医学] 1001[医学-基础医学(可授医学、理学学位)] 100104[医学-病理学与病理生理学] 100215[医学-康复医学与理疗学] 10[医学]
基 金:This study was supported by the Rio Grande do Sul Science Foundation(FAPERGS),grants#16/2551-0000207-0 and 16/0526-5(PRONUPEQ)(to SP) National Counsel of Technological and Scientific Development(CNPq)(Universal grants#423435/2016-7 and 460122/2014-2)and for student scholarships(to CL,SEH and DSÁ).
主 题:Alzheimer’s disease curcumin cyclooxygenase-2 lipid core nanocapsules meloxicam memory rats inflammation
摘 要:Alzheimer’s disease is a progressive brain disorder and complex mechanisms are involved in the physiopathology of Alzheimer’s disease.However,there is data suggesting that inflammation plays a role in its development and progression.Indeed,some non-steroidal antiinflammatory drugs,such as meloxicam,which act by inhibiting cyclooxygenase-2 have been used as neuroprotective agents in different neurodegenerative disease models.The purpose of this study was to investigate the effects of co-nanoencapsulated curcumin and meloxicam in lipid core nanocapsules(LCN)on cognitive impairment induced by amyloid-beta peptide injection in *** were prepared by the nanoprecipitation method.Male Swiss mice received a single intracerebroventricular injection of amyloid-beta peptide aggregates(fragment 25–35,3 nmol/3μL)or vehicle and were subsequently treated with curcumin-loaded LCN(10 mg/kg)or meloxicam-loaded LCN(5 mg/kg)or meloxicam+curcumin-co-loaded LCN(5 and 10 mg/kg,respectively).Treatments were given on alternate days for 12 days(i.e.,six doses,once every 48 hours,by intragastric gavage).Our data showed that amyloid-beta peptide infusion caused long-term memory deficits in the inhibitory avoidance and object recognition tests in mice.In the inhibitory avoidance test,both meloxicam and curcumin formulations(oil or co-loaded LCN)improved amyloid-beta-induced memory impairment in mice.However,only meloxicam and curcumin-co-loaded LCN attenuated non-aversive memory impairment in the object recognition test.Moreover,the beneficial effects of meloxicam and curcuminco-loaded LCN could be explained by the anti-inflammatory properties of these drugs through cortical cyclooxygenase-2 downregulation.Our study suggests that the neuroprotective potential of meloxicam and curcumin co-nanoencapsulation is associated with cortical cyclooxygenase-2 modulation.This study was approved by the Committee on Care and Use of Experimental Animal Resources,the Federal University of Pampa,Brazil(approval No.02-2015)on April 16,2015.